Fig. 9. Illustration of the relationship between the sales of thalidomide (broken line) and the number of malformations typical of thalidomide embryopathy (solid line). (Lenz W: Discussion in Symposium on Embryopathic Activity of Drugs. Robson JM, Sullivan FM, Smith RL(eds): Eur J Obstet Gynecol Reprod Biol 16:365, 1984)